Halozyme's (HALO) HTI-501 significantly improved the appearance of cellulite on patients' skin in a Phase I/II trial, thereby meeting the main goal of the study.
Halozyme's effect was compared with a control vehicle and with the skin prior to treatment.
The effect was maintained at three and six months.
Share are +5.5% premarket. (PR)